Cerus (CERS) Reports In-Line Q1 EPS

Cerus (NASDAQ: CERS) reported Q1 EPS of ($0.10), in-line with the analyst e

“First quarter product revenue of $18.6 million exceeded our internal expectations despite the tumultuous macro environment created by the global COVID-19 pandemic. The emergence of SARS-CoV-2 has highlighted the need for comprehensive preparedness planning for healthcare systems and the corresponding obligation to safeguard the blood supply chain. The INTERCEPT Blood System has played a critical role for many blood centers by reducing the risk of transfusion transmitted infections,” said William ‘Obi’ Greenman, Cerus’ president and chief executive officer. “In the face of this crisis, I am proud of the actions taken by the Cerus employees designed to make sure that the blood centers and hospitals have access to INTERCEPT Blood System, even in the regions hardest hit by the pandemic.”

“It is unclear as to the extent and duration that the COVID-19 impact will have on the global transfusion medicine industry and on healthcare in general, but given the critical need for blood and blood components, we are cautiously optimistic about the health of our business and our ability to further our mission to make INTERCEPT the standard of care,” continued Greenman.

timate of ($0.10). Revenue for the quarter came in at $24.6 million versus the consensus estimate of $23.12 million.

For earnings history and earnings-related data on Cerus (CERS) click here.

You May Also Be Interested In

• Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
• Southern First Bancshares, Inc. (SFST) Misses Q1 EPS by 8c
• P.A.M. Transportation Services (PTSI) Misses Q1 EPS by 9c